IL153236A0 - The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders - Google Patents

The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Info

Publication number: IL153236A0
Authority: IL; Israel
Prior art keywords: copolymer; treatment; nervous system; central nervous; system disorders
Prior art date: 2000-06-05

Application number

IL15323601A

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-05

Filing date

2001-06-05

Publication date

2003-07-06

2001-06-05 Application filed by Teva Pharma filed Critical Teva Pharma

2003-07-06 Publication of IL153236A0 publication Critical patent/IL153236A0/en

Links

108010072051 Glatiramer Acetate Proteins 0.000 title 1
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title 1
208000015114 central nervous system disease Diseases 0.000 title 1
229920001577 copolymer Polymers 0.000 title 1
229960003776 glatiramer acetate Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL15323601A 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders IL153236A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58752300A	2000-06-05	2000-06-05
PCT/US2001/018248 WO2001093828A1 (en)	2000-06-05	2001-06-05	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Publications (1)

Publication Number	Publication Date
IL153236A0 true IL153236A0 (en)	2003-07-06

Family

ID=24350145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15323601A IL153236A0 (en)	2000-06-05	2001-06-05	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Country Status (9)

Country	Link
EP (1)	EP1292279A4 (en)
JP (1)	JP2003535118A (en)
AU (2)	AU7528001A (en)
CA (1)	CA2411536A1 (en)
HU (1)	HUP0302333A3 (en)
IL (1)	IL153236A0 (en)
PL (1)	PL363431A1 (en)
WO (1)	WO2001093828A1 (en)
ZA (1)	ZA200210084B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (en)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Treatment of Crohn's disease with copolymer 1 and polypeptides
CA2337688C (en)	1998-07-23	2016-04-05	Yeda Research And Development Co., Ltd.	Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en)	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP4369234B2 (en)	2001-12-04	2009-11-18	テバファーマシューティカルインダストリーズリミティド	Method for measuring the strength of glatiramer acetate
DK1797109T3 (en)	2004-09-09	2016-04-11	Yeda Res & Dev	MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
EP2405749B1 (en)	2009-08-20	2013-05-08	Yeda Research and Development Co., Ltd.	Low frequency glatiramer acetate therapy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
BR112013008573A2 (en)	2010-10-11	2016-07-12	Teva Pharma	biomarker cytokines as indicators of clinical response to glatiramer acetate.
CN103957705A (en)	2011-10-10	2014-07-30	泰华制药工业有限公司	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
MX2015004563A (en)	2012-10-10	2015-07-14	Teva Pharma	Biomarkers predictive for clinical response for glatiramer acetate.
UY35790A (en)	2013-10-21	2015-05-29	Teva Pharma	GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
DK3185882T3 (en)	2014-08-29	2020-01-27	Region Midtjylland	Positively charged copolymers for use as antimicrobial agents
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
CN106924175B (en) *	2015-12-29	2020-07-03	深圳翰宇药业股份有限公司	Pharmaceutical composition for treating multiple sclerosis
KR102425326B1 (en)	2016-05-20	2022-07-25	세다르스-신나이 메디칼 센터	Methods for treating or preventing Alzheimer's disease and related conditions
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
FI3506921T3 (en)	2016-08-31	2023-07-21	Mapi Pharma Ltd	Depot systems comprising glatiramer acetate
MX2019010174A (en)	2017-03-26	2019-10-15	Mapi Pharma Ltd	Glatiramer depot systems for treating progressive forms of multiple sclerosis.
CN115151271A (en) *	2020-09-27	2022-10-04	长沙英奈发药业有限公司	Application of glatiramer acetate in preparation of Abeta 42 toxicity inhibitor and scavenger

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
GB9411292D0 (en) *	1994-06-06	1994-07-27	Teva Pharma	Pharmaceuticals compositions
US5665764A (en) *	1995-06-02	1997-09-09	Warner-Lambert Company	Tricyclic inhibitors of matrix metalloproteinases
IL119989A0 (en) *	1997-01-10	1997-04-15	Yeda Res & Dev	Pharmaceutical compositions for oral treatment of multiple sclerosis
ES2243450T3 (en) *	2000-01-20	2005-12-01	Yeda Research And Development Co. Ltd.	THE USE OF COPOLIMERO 1 AND PEPTIDES AND RELATED POLYPEPTIDES, AND OF T-CELLS TREATED WITH THE SAME, FOR NEUROPROTECTOR THERAPY.
MXPA02007109A (en) *	2000-06-07	2002-12-13	Yeda Res & Dev	THE USE OF COPOLYMER 1 AND RELATED PEPTIDES AND POLYPEPTIDES AND T-CELLS TREATED WITH THESE TO PROTECT THE CENTRAL NERVOUS SYSTEM CELLS FROM THE TOXICITY OF GLUTAMATE.

2001
- 2001-06-05 IL IL15323601A patent/IL153236A0/en unknown
- 2001-06-05 HU HU0302333A patent/HUP0302333A3/en unknown
- 2001-06-05 CA CA002411536A patent/CA2411536A1/en not_active Abandoned
- 2001-06-05 WO PCT/US2001/018248 patent/WO2001093828A1/en not_active Ceased
- 2001-06-05 EP EP01941973A patent/EP1292279A4/en not_active Withdrawn
- 2001-06-05 AU AU7528001A patent/AU7528001A/en active Pending
- 2001-06-05 AU AU2001275280A patent/AU2001275280B2/en not_active Ceased
- 2001-06-05 JP JP2002501401A patent/JP2003535118A/en active Pending
- 2001-06-05 PL PL01363431A patent/PL363431A1/en not_active Application Discontinuation
2002
- 2002-12-12 ZA ZA200210084A patent/ZA200210084B/en unknown

Also Published As

Publication number	Publication date
PL363431A1 (en)	2004-11-15
ZA200210084B (en)	2003-12-12
EP1292279A1 (en)	2003-03-19
CA2411536A1 (en)	2001-12-13
EP1292279A4 (en)	2005-01-12
AU2001275280B2 (en)	2006-03-16
HUP0302333A2 (en)	2003-11-28
JP2003535118A (en)	2003-11-25
WO2001093828A1 (en)	2001-12-13
AU7528001A (en)	2001-12-17
HUP0302333A3 (en)	2005-07-28

Similar Documents

Publication	Publication Date	Title
AU7528001A (en)	2001-12-17	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0100069A3 (en)	2002-04-29	4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0004439A3 (en)	2001-12-28	1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
AU9112201A (en)	2002-04-02	Pulmonary delivery in treating disorders of the central nervous system
HUP0100786A3 (en)	2002-12-28	Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
IL151946A0 (en)	2003-04-10	2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0401023A3 (en)	2004-10-28	Use of flibanserin in the treatment of sexual disorders
IL187513A0 (en)	2008-06-05	Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
EP0924983A4 (en)	1999-08-25	S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
IL155589A0 (en)	2003-11-23	Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2001266152A1 (en)	2002-01-02	Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
ZA97741B (en)	1997-07-30	Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2001256855A1 (en)	2001-11-20	Preparation for the prevention and treatment of ocular disorders
IL150289A0 (en)	2002-12-01	Drug combination for the treatment of depression and related disorders comprising mirtazapine
IL160018A0 (en)	2004-06-20	Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
GB0015228D0 (en)	2000-08-16	Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
HUP0302194A3 (en)	2005-12-28	Chemokine mutants in the treatment of multiple sclerosis
EP1079764A4 (en)	2001-09-12	The treatment of sexual dysfunction in certain patient groups
HUP0301553A3 (en)	2005-05-30	Pharmaceutical compositions and their use for treating neurological disorders
AU2002226060A1 (en)	2002-06-18	Compositions containing gangliosides for use in the treatment of skin disorders
IL129460A0 (en)	2000-02-29	Use of lofexidine in the treatment of behavioral disorders
AU2002210763A1 (en)	2002-05-15	Use of 1-ebio in the treatment of bipolar disorders
AU6330300A (en)	2001-01-30	Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
AU2001292500A1 (en)	2002-04-08	1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
ZA9610264B (en)	1998-06-08	Preparation for use in the treatment of skin disorders.